U.S., Jan. 9 -- ClinicalTrials.gov registry received information related to the study (NCT07327632) titled 'This is a Multi-Center Study of IBI3026 in Participants With Locally Advanced, Unresectable or Metastatic Solid Tumors' on Dec. 26, 2025.
Brief Summary: This is a multicenter, open-label, phase I dose-escalation and expansion study of IBI3026 in participants with unresectable, locally advanced, or metastatic solid tumors. The study will be conducted in two phases: Phase 1 dose escalation and Phase 2 dose expansion. Safety will be monitored by the Safety Review Committee (SRC).
Study Start Date: Jan. 31
Study Type: INTERVENTIONAL
Condition:
Solid Tumor
Intervention:
DRUG: IBI3026
Recombinant anti-programmed death receptor-1 (PD...